The verbal sparring persists regarding mobile insulin pumps used by high numbers of U.S. consumers. Legions of those individuals are children. Reportedly, about 250,000 adolescents across the country use pumps manufactured by Medtronic Inc., the leading device maker.
Unsurprisingly, Medtronic touts the safety of its product, given its sheer market clout and popularity stamped over many years. Company executives routinely state that users’ reported adverse-use incidents owe to their own ignorance or negligence in using the pumps.
There seems to be some evidence of that, but there is also this, as noted in one national article that recently took a deep dive into pump use and reported malfunctions: Medtronic has received “more than 150,000 reports of deaths or injuries related to insulin pumps since 2008.”
That harrowingly high number reasonably belies assertions that consumers’ pump use is repeatedly incorrect – over and over for many years running. Even if it were, the recurrences should have had Medtronic deeply concerned long ago and intent on making pump interactions simpler and more effective.
The stated concerns with the pumps are obviously as concerning in Kentucky as they are elsewhere.
Indeed, there seems to be a copious amount of compelling evidence that Medtronic’s product is flawed in a manner that makes it potentially dangerous in a given case and requires periodic tweaking.
Here’s a shred of that evidence: the device maker has been the named defendant in approximately 100 defective-products lawsuits within the past 10 years. Moreover (and this is unquestionably telling), pumps have been recalled a staggering 20 times over that same period.
Such performance might logically invite consumer mistrust and a lack of confidence using the product.
We will keep readers of our pro-victims’ product liability blog in Connecticut and elsewhere duly updated on future material developments concerning this important safety-linked subject.